FDA granted Breakthrough Therapy designation to LEE011 (ribociclib), in combination with letrozole, for the treatment of hormone receptor positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer. LEE011 is a selective cyclin dependent kinase (CDK4/6) inhibitor.
In 1996, Lei Zheng, a graduate of Peking Union Medical College, enrolled in the doctorate program at what was then known as the Cancer Therapy & Research Center in San Antonio.
